Cited by 25Hemoglobinopathies and Related DisordersBlood groups and transfusionNeonatal Health and Biochemistry

Prognostic factors of disease severity in infants with sickle cell anemia: A comprehensive longitudinal cohort study

Open access
Brousse, Valentine, El Hoss, Sara, Bouazza, Naïm, Arnaud, Cécile, Bernaudin, Francoise, Pellegrino, Béatrice, Guitton, Corinne, Odièvre‐Montanié, Marie‐Hélène +17 more·2018·American Journal of Hematology

Abstract

In order to identify very early prognostic factors that can provide insights into subsequent clinical complications, we performed a comprehensive longitudinal multi‐center cohort study on 57 infants with sickle cell anemia (55 SS; 2 Sβ°) during the first 2 years of life (ClinicalTrials.gov: NCT01207037). Time to first occurrence of a severe clinical event—acute splenic sequestration (ASS), vaso‐occlusive (VOC) event requiring hospitalization, transfusion requirement, conditional/ abnormal cerebral velocities, or death—was used as a composite endpoint. Infants were recruited at a mean age of 4.4 ±1 months. Median follow‐up was 19.4 months. During the study period, 38.6% of infants experienced ≥1 severe event: 14% ASS, 22.8% ≥ 1 VOC (median age: 13.4 and 12.8 months, respectively) and 33.3% required transfusion. Of note, 77% of the cohort was hospitalized, with febrile illness being the leading cause for admission. Univariate analysis of various biomarkers measured at enrollment showed that fetal hemoglobin (HbF) was the strongest prognostic factor of subsequent severe outcome. Other biomarkers measured at enrolment including absolute neutrophil or reticulocyte counts, expression of erythroid adhesion markers, % of dense red cells, cellular deformability or ϒ‐globin genetic variants, failed to be associated with severe clinical outcome. Multivariate analysis demonstrated that higher Hb concentration and HbF level are two independent protective factors (adjusted HRs (95% CI) 0.27 (0.11‐0.73) and 0.16 (0.06‐0.43), respectively). These findings imply that early measurement of HbF and Hb levels can identify infants at high risk for subsequent severe complications, who might maximally benefit from early disease modifying treatments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ajh.25260

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In 57 infants studied at 4.4±1 months of age and followed for approximately 19 months, HbF fell from 42% to 21% and was the strongest prognostic factor for disease complications.

    “To identify prognostic factors for clinical complications, 57 infants were studied at 4.4 6 1 months of age and followed for ;19 months.HbF, which fell from 42% to 21% during the observation period, was the strongest prognostic factor for disease complications.64”

    From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [64]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [2]2. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell dis- ease. Lancet. 2017;390:311-323.

Cited by

Sorted by citations

Authors
Brousse, V., El Hoss, S., Bouazza, N., Arnaud, C., Bernaudin, F., Pellegrino, B., Guitton, C., Odièvre‐Montanié, M., Mames, D., Brouzes, C., Picard, V., Nguyen‐Khoa, T., Pereira, C., Lapouméroulie, C., Pissard, S., Gardner, K., Menzel, S., Le Van Kim, C., Colin‐Aronovicz, Y., Buffet, P., Mohandas, N., Elie, C., Maier‐Redelsperger, M., El Nemer, W., & de Montalembert, M.
Affiliations
  • Hôpital Necker-Enfants Malades (FR)
  • UMR_S 1134 Biologie Intégrée du Globule Rouge Université Sorbonne Paris Cité/Université Paris Diderot/INSERM/INTS/Laboratoire d'Excellence GR‐Ex Paris France
  • Sorbonne Paris Cité (FR)
  • Hôpital Intercommunal de Créteil (FR)
  • Service de Pédiatrie Centre Hospitalier Intercommunal de Créteil Créteil France
  • Centre Hospitalier Intercommunal de Poissy (FR)
  • Bicêtre Hospital (FR)
  • Service de Pédiatrie, Hôpital Universitaire Armand Trousseau Paris France
  • Hôpital Tenon (FR)
  • Inserm (FR)
  • Centre Hospitalier Universitaire Henri-Mondor (FR)
  • King's College London (GB)
  • New York Blood Center (US)
  • Hôpital Cochin (FR)
  • Laboratoire d'Hématologie Hôpital Universitaire Tenon Paris France
  • Service de Pédiatrie et Maladies Infectieuses Hôpital Universitaire Necker‐Enfants Malades Paris France
Corresponding author
Brousse, Valentine
Venue
American Journal of Hematology
Publisher
Wiley
Published
2018-09-21
Volume
93
Issue
11
Pages
1411-1419
ISSN
  • 0361-8609 (ISSN-L)
  • 1096-8652
OpenAlex
W2888059503
Cited by
25
References
31
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 3 · 2020: 1 · 2019: 4 · 2018: 1
FWCI
1.27
Type
journal article
Language
en
Open access
Locations
  • American Journal of Hematology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • “Investissements d'avenir” of the French National Research Agency (ANR-11-IDEX-0005-02)
  • Laboratory of Excellence GR-Ex (ANR-11-LABX-0051)
  • Département de la Recherche Clinique et du Développement de l'Assistance Publique-Hôpitaux de Paris
  • French Ministry of Health (P071228)
Topics
  • Health Sciences › Medicine › Genetics › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
Keywords
sickle cell disease, infants, prognostic factors, fetal hemoglobin, hemoglobin levels, acute splenic sequestration, vaso-occlusive crisis, transfusion requirements, cerebral blood flow velocity, hemoglobin S-beta thalassemia, disease severity, early biomarkers
MeSH terms
Anemia, Sickle Cell, Blood Transfusion, Female, Fetal Hemoglobin, Hemoglobins, Hospitalization, Humans, Infant, Longitudinal Studies, Male, Prognosis, Severity of Illness Index, Cohort Studies, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review